These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy. He J; Tang XF; Chen QY; Mai HQ; Huang ZF; Li J; Zeng YX Chin J Cancer; 2012 Jun; 31(6):287-94. PubMed ID: 22257383 [TBL] [Abstract][Full Text] [Related]
4. Augmentation of pokeweed mitogen-induced immunoglobulin production by cord T-cell supernatants. Brazil J; Puri P; Reen DJ Biol Neonate; 1985; 47(1):36-41. PubMed ID: 3871338 [TBL] [Abstract][Full Text] [Related]
5. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282 [TBL] [Abstract][Full Text] [Related]
6. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. Kooi S; Freedman RS; Rodriguez-Villanueva J; Platsoucas CD Lymphokine Cytokine Res; 1993 Dec; 12(6):429-37. PubMed ID: 8123759 [TBL] [Abstract][Full Text] [Related]
7. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877 [TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus LMP1 status in relation to apoptosis, p53 expression and leucocyte infiltration in nasopharyngeal carcinoma. Shao JY; Ernberg I; Biberfeld P; Heiden T; Zeng YX; Hu LF Anticancer Res; 2004; 24(4):2309-18. PubMed ID: 15330177 [TBL] [Abstract][Full Text] [Related]
9. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009 [TBL] [Abstract][Full Text] [Related]
10. [Evaluation of combined determinations of Epstein-Barr virus antibodies for nasopharyngeal carcinoma assessed with receiver operating characteristic curve based on logistic regression]. Cai YL; Zheng YM; Cheng JR; Li J; Mo YK; Zhong QY Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Oct; 23(5):384-7. PubMed ID: 20387494 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC). Liu MT; Yeh CY Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898 [TBL] [Abstract][Full Text] [Related]
12. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups. Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990 [TBL] [Abstract][Full Text] [Related]
13. T-cell immunoregulation in patients with inflammatory bowel disease. II. Enhanced suppressor T-cell activity in ulcerative colitis. Kramer JK; Depew WT; Szewczuk MR J Clin Lab Immunol; 1988 Jan; 25(1):19-27. PubMed ID: 2968458 [TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid lymphocytes from patients with multiple sclerosis do not increase immunoglobulin or measles antibody production after stimulation with pokeweed mitogen. Henriksson A; Kam-Hansen S; Forsberg P; Grandien M J Neuroimmunol; 1986 Mar; 11(1):15-30. PubMed ID: 3944248 [TBL] [Abstract][Full Text] [Related]
15. [Evaluation of detection of Epstein-Barr virus Rta/IgG in nasopharyngeal carcinoma]. Zheng YM; Cain YL; Cheng JR; Li J; Mo YK; Gao JQ; Dong ZR; Zhong QY Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Aug; 23(4):285-7. PubMed ID: 20108775 [TBL] [Abstract][Full Text] [Related]
16. Interleukin-4 suppresses immunoglobulin production by peripheral blood lymphocytes of patients with common variable immunodeficiency (CVI) induced by supernatants of T cell clones. Pastorelli G; Roncarolo MG; Touraine JL; Rousset F; Pene J; de Vries JE Clin Exp Immunol; 1989 Dec; 78(3):341-7. PubMed ID: 2575470 [TBL] [Abstract][Full Text] [Related]
17. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma. Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566 [TBL] [Abstract][Full Text] [Related]
18. Quantification of Epstein-Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-beta1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma. Tan EL; Selvaratnam G; Kananathan R; Sam CK BMC Cancer; 2006 Sep; 6():227. PubMed ID: 16995954 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma. Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473 [TBL] [Abstract][Full Text] [Related]
20. Regulation of human immunoglobulin production in vitro by prostaglandin E2. Staite ND; Panayi GS Clin Exp Immunol; 1982 Jul; 49(1):115-22. PubMed ID: 6957277 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]